The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections
Abstract
In recent years, bacteriophages (or phages) have reentered the spotlight as alternative or adjuvant therapeutic agents to antibiotics. Their efficacy in more recalcitrant forms of infections like biofilms, frequently encountered in the orthopedic setting, remains less characterized. The present study aimed at evaluating the activity of phage-antibiotic combinations against Pseudomonas aeruginosa biofilms. A large collection of phages was de novo isolated from a wide variety of environmental sources. Three phages with a large host range against a.o. clinical orthopedic isolates, PSP2 ( Yuavirus ), PSP3 ( Pbunavirus ), and PSP30 ( Bruynoghevirus ), were selected for phage-antibiotic synergy assays on mature P. aeruginosa PAO1 biofilms. Phages were combined with ciprofloxacin, meropenem, and ceftazidime, all used as standard of care in bone-related infections. Significant reductions in both cell counts and biomass were observed for all phage-antibiotic combinations. The highest reduction in viable cell counts was observed for PSP3 and PSP2 in combination with ceftazidime [4.58 and 4.30 log 10 Colony Forming Units (CFU)/well], followed by all phage combinations with ciprofloxacin (up to 3.56 log 10 CFU/well). The highest reduction in biomass was obtained by combining PSP3 with ciprofloxacin (29.8%). Metabolic assays confirmed these findings with reductions in biofilm respiratory rate of up to 65%. Scanning electron microscopy imaging of PAO1 biofilms grown on titanium coupons and treated by ciprofloxacin and PSP30 confirmed the efficacy of the combined treatment with PSP30 and ciprofloxacin. This study highlights the synergetic effects of phage-antibiotic combinations on P. aeruginosa biofilms, thereby offering a promising approach to combat biofilm-associated infections. IMPORTANCE: Biofilm-related infections are among the most difficult-to-treat infections in all fields of medicine due to their antibiotic tolerance and persistent character. In the field of orthopedics, these biofilms often lead to therapeutic failure of medical implantable devices and urgently need novel treatment strategies. This forthcoming article aims to explore the dynamic interplay between newly isolated bacteriophages and routinely used antibiotics and clearly indicates synergetic patterns when used as a dual treatment modality. Biofilms were drastically more reduced when both active agents were combined, thereby providing additional evidence that phage-antibiotic combinations lead to synergism and could potentially improve clinical outcome for affected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vitro and in vivo models that include zebrafish and murine airway and implant systems show accelerated clearance and improved survival, with reduced emergence of resistance [213,214,215].”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [213]
In the citing paper
“Phage antibiotic combinations often outperform either alone.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [213]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Explosive cell lysis as a mechanism for the biogenesis of bacterial membrane vesicles and biofilms
Turnbull, L., Toyofuku, M., Hynen, A. L., Kurosawa, M., Pessi, G., Petty, N. K., Osvath, S. R., Cárcamo-Oyarce, G., Gloag, E. S., Shimoni, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11220 · Cited by 709
Research works printed but not linked: 90
- 10.3390/v10020064 · DOI · Paper page
- 10.1007/s00284-016-1166-x · DOI · Paper page
- 10.3390/antibiotics9110795 · DOI
- 10.1038/nrmicro.2016.94 · DOI · Paper page
- 10.1128/JB.182.10.2675-2679.2000 · DOI · Paper page
- 10.1002/jor.24019 · DOI
- 10.1016/j.heliyon.2018.e01067 · DOI · Paper page
- 10.1016/j.cmi.2014.10.024 · DOI · Paper page
- 10.1086/668421 · DOI
- 10.1302/2058-5241.4.180092 · DOI
- 10.7759/cureus.15634 · DOI
- 10.23750/abm.v88i2-S.6518 · doi:10.23750/abm.v88i2-s.6518
- 10.1007/s11914-019-00548-4 · DOI · Paper page
- 10.3389/fmed.2020.513242 · doi:10.3389/fmed.2020.513242
- 10.1093/ofid/ofad051 · doi:10.1093/ofid/ofad051
- 10.1016/j.copbio.2021.02.002 · DOI
- 10.1371/journal.pone.0007740 · DOI · Paper page
- 10.1007/s00253-017-8224-6 · DOI · Paper page
- 10.1021/acsptsci.0c00045 · DOI
- 10.3390/v13101965 · DOI
- 10.3390/v11100891 · DOI · Paper page
- 10.3390/antibiotics8030103 · DOI · Paper page
- 10.1208/s12248-019-0315-0 · DOI
- 10.1007/s12250-019-00192-3 · DOI
- 10.3389/fmicb.2015.01315 · DOI
- 10.3390/v10080438 · DOI
- 10.3390/antibiotics11070839 · DOI
- 10.2147/NSA.S325594 · DOI
- 10.3390/antibiotics12030497 · DOI
- 10.1186/s12864-017-3729-z · DOI
- 10.1089/phage.2020.0015 · doi:10.1089/phage.2020.0015
- 10.1371/journal.pone.0000799 · DOI
- 10.1002/em.22267 · DOI · Paper page
- 10.3855/jidc.12094 · DOI
- 10.1128/AEM.02850-14 · DOI · Paper page
- 10.1128/AAC.00900-21 · doi:10.1128/aac.00900-21
- 10.1007/s10068-016-0153-0 · doi:10.1007/s10068-016-0153-0
- 10.1007/s10068-016-0192-6 · DOI
- 10.1128/AAC.00461-20 · doi:10.1128/aac.00461-20
- 10.3390/antibiotics10020174 · DOI
- 10.3390/v13101898 · DOI
- 10.1089/mdr.2021.0324 · DOI
- 10.3390/antibiotics10070849 · DOI
- 10.3390/antibiotics9110749 · doi:10.3390/antibiotics9110749
- 10.3389/fmicb.2018.00127 · DOI
- 10.1139/cjm-2022-0080 · DOI
- 10.1128/spectrum.00096-22 · DOI
- 10.1016/j.ebiom.2022.104045 · DOI · Paper page
- 10.3390/microorganisms7110556 · doi:10.3390/microorganisms7110556
- 10.3390/v11100954 · DOI
- 10.1128/AAC.00993-20 · DOI
- 10.3390/antibiotics11091175 · DOI
- 10.3390/antibiotics11030392 · DOI
- 10.1007/s00705-018-3811-0 · doi:10.1007/s00705-018-3811-0
- 10.1128/AEM.02085-18 · doi:10.1128/aem.02085-18
- 10.1016/j.ijpharm.2018.09.024 · DOI
- 10.3389/fcimb.2019.00022 · DOI · Paper page
- 10.3390/microorganisms9010152 · DOI
- 10.3390/ph14030184 · DOI
- 10.3390/antibiotics10080946 · doi:10.3390/antibiotics10080946
- 10.1038/s41467-022-33294-w · DOI · Paper page
- 10.1111/jam.15647 · DOI
- 10.1371/journal.pone.0168615 · DOI · Paper page
- 10.1128/spectrum.04636-22 · DOI
- 10.1016/j.micpath.2019.01.032 · DOI
- 10.1016/j.bpc.2020.106456 · DOI
- 10.1100/2012/402919 · DOI
- 10.1186/s12941-020-00389-5 · DOI · Paper page
- 10.3389/fmicb.2020.00327 · DOI · Paper page
- 10.1016/j.jmb.2022.167670 · doi:10.1016/j.jmb.2022.167670
- 10.1016/j.envres.2023.116586 · doi:10.1016/j.envres.2023.116586
- 10.1128/mBio.01462-20 · DOI · Paper page
- 10.1038/nrmicro.2017.61 · DOI · Paper page
- 10.1128/AEM.00757-12 · DOI · Paper page
- 10.3389/fmicb.2021.613529 · DOI
- 10.3389/fcimb.2017.00418 · DOI · Paper page
- 10.2217/fmb.13.47 · DOI · Paper page
- 10.1101/2023.01.23.22283996 · doi:10.1101/2023.01.23.22283996
- 10.1111/j.1462-2920.2009.02030.x · DOI
- 10.1128/JB.01441-07 · doi:10.1128/jb.01441-07
- 10.1080/1040841X.2016.1208146 · DOI · Paper page
- 10.1007/s10096-023-04638-1 · DOI
- 10.1007/978-1-60327-164-6_2 · DOI · Paper page
- 10.1007/978-1-60327-164-6_14 · DOI · Paper page
- 10.3389/fmicb.2020.594868 · DOI
- 10.1186/s12859-023-05341-w · DOI
- 10.1101/2023.02.24.529883 · doi:10.1101/2023.02.24.529883
- 10.1016/j.jmb.2017.12.007 · DOI · Paper page
- 10.1128/AAC.02149-21 · DOI
- 10.1128/spectrum.04671-22 · doi:10.1128/spectrum.04671-22
Cited by
Bacterial persisters: molecular mechanisms and therapeutic development
Niu, H., Gu, J., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01866-5 · Cited by 310
Elbehiry, A., Marzouk, E., Edrees, H. M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., Jaber, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010109 · Cited by 34
Metadata
- Authors
- De Soir, S., Parée, H., Kamarudin, N. H. N., Wagemans, J., Lavigne, R., Braem, A., Merabishvili, M., De Vos, D., Pirnay, J.-P., & Van Bambeke, F.
- Affiliations
- Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain , Brussels, Belgium
- Department of Materials Engineering, Biomaterials and Tissue Engineering Research Group, KU Leuven , Leuven, Belgium
- Laboratory of Gene Technology, KU Leuven , Leuven, Belgium
- Laboratory for Molecular and Cellular Technology (LabMCT), Queen Astrid Military Hospital , Neder-over-Heembeek, Belgium
- Venue
- Microbiology Spectrum
- Publisher
- American Society for Microbiology
- Published
- 2024-01-11
- Volume
- 12
- Issue
- 1
- ISSN
- 2165-0497
- Cited by
- 36
- References
- 2
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Funders
- Innoviris (2019-PHD-9)
- Fonds De La Recherche Scientifique - FNRS (J.0177.23, J.0162.19)
- Fonds Wetenschappelijk Onderzoek (W000921N)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections. https://app.cochat.ai/papers/10.1128/spectrum.03219-23
- The paper
- De Soir, S., Parée, H., Kamarudin, N. H. N., Wagemans, J., Lavigne, R., Braem, A., Merabishvili, M., De Vos, D., Pirnay, J.-P., & Van Bambeke, F. (2024). Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03219-23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.